TMCnet News

$25,230 Million Hypercalcemia Treatment Market: Global Industry Analysis & Opportunity Assessment, 2016-2026 - Research and Markets
[February 01, 2017]

$25,230 Million Hypercalcemia Treatment Market: Global Industry Analysis & Opportunity Assessment, 2016-2026 - Research and Markets


Research and Markets has announced the addition of the "Hypercalcemia Treatment Market: Global Industry Analysis & Opportunity Assessment, 2016-2026" report to their offering.

Global hypercalcemia treatment market revenue is projected to expand at a CAGR of 11.2% during forecast period 2016-2026, and a reach a value of US$ 25,230.2 Mn by the end of 2026.

Early diagnosis of hypercalcemia by hydration and treatment with agents - to decrease serum calcium concentrations - also known as hypocalcemic drugs can produce symptomatic improvements within three to five days. The scope of hypercalcemia treatment market study is for Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate and Zoledronic acid), Calcitonin, Glucocorticoids, Denosumab and Calcimimetics for treatment of malignancy-related hypercalcemia.

Primary factors fuelling demand for hpercalcemia treatment include increasing prevalence of hyperparathyroidism-related hypercalcemia, growing number of patients with cancers, higher incidence of multiple myeloma, availability of appropriate drug therapy alternatives over surgery, favourable reimbursement scenario and drug therapies to avoid kidney failure.



Based on product type, the market has been segmented into Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate and Zoledronic acid), Calcitonin, Glucocorticoids, Denosumab and Calcimimetics.

Revenue from the independent pharmacy and drug stores segment is expected to grow at a very fast pace, and contribute significantly towards distribution of hypercalcemia drugs during the forecast period. Hospitals distribution channel segment is projected to generate comparatively high revenue owing to novel and easy availability of hypercalcemia treatment drugs worldwide.


Some key players in the global hypercalcemia treatment market that have been identified in this report include Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy's Laboratories Ltd. and Cipla Inc. The report also identifies company-specific strategies related to market consolidation initiatives and analysis of their specific strengths, weaknesses, opportunities and threats.

For more information about this report visit http://www.researchandmarkets.com/research/5bjf6g/hypercalcemia


[ Back To TMCnet.com's Homepage ]